Diabetes-related stocks take hit over weight loss drug craze

This segment originally aired on October 5, 2023
Weight loss drugs, like Novo Nordisk's (NVO) Ozempic, have become popular across healthcare providers in regard to diabetes treatment. Although use is limited due to affordability, shares of diabetes drugmakers (DXCM, PODD, TNDM) have seen declines while Ozempic has been a favored choice for consumers. Yahoo Finance Health Reporter Anjalee Khemlani explains the growing hype around the drugs and provides insight into what it means for the future of diabetic patients, while also commenting on the demand drops for insulin pumps and glucose monitors. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Subscribe to Yahoo Finance: yhoo.it/2fGu5Bb
About Yahoo Finance:
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
To learn more about Yahoo Finance Plus please visit: yhoo.it/33jXYBp
Connect with Yahoo Finance:
Get the latest news: yhoo.it/2fGu5Bb
Find Yahoo Finance on Facebook: bit.ly/2A9u5Zq
Follow Yahoo Finance on Twitter: bit.ly/2LMgloP
Follow Yahoo Finance on Instagram: bit.ly/2LOpNYz
Follow Yahoo Finance Premium on Twitter: bit.ly/3hhcnmV

[@bog6106]

Abusing drugs for something they are not intended to be used for always ends well

[@billsmith5166]

Lot's of drugs started off being used off-label.

[@user-yy9hk9od9u]

Good.